Insmed

Aktuelle Nachrichten

Schlagzeilen in der Originalsprache der Quelle.

• Insmed Price Target Cut to $207.00/Share From $237.00 by Barclays (öffnet in neuem Tab)

  Moomoo · 30.09.2026

• Barclays Maintains Insmed(INSM.US) With Buy Rating, Cuts Target Price to $207 (öffnet in neuem Tab)

  Moomoo · 30.09.2026

• Insmed TPIP shows sustained improvement in PAH study (öffnet in neuem Tab)

  scanx.trade · 28.09.2026

• Insmed 15-year return: $1,000 investment grows to $27,361 (öffnet in neuem Tab)

  scanx.trade · 28.09.2026

• $1000 Invested In Insmed 15 Years Ago Would Be Worth This Much Today (öffnet in neuem Tab)

  Benzinga · 28.09.2026

• Insmed (INSM) Gets Faster FDA Review. Can Its Lung Drug Reach More Patients? (öffnet in neuem Tab)

  Yahoo Finance · 28.09.2026

• Insmed (INSM) Could Be 40% Undervalued On FDA Priority Review News (öffnet in neuem Tab)

  Simply Wall Street · 28.09.2026

• Why Insmed (INSM) Stock Is Down Today (öffnet in neuem Tab)

  Quiver Quantitative · 25.09.2026

• Goldman Sachs initiates Insmed stock coverage with buy rating, $188 target (öffnet in neuem Tab)

  Investing.com · 24.09.2026

• Learn Why The Bull Case For Insmed Stock Could Change Following Priority Review Acceptance (öffnet in neuem Tab)

  Simply Wall Street · 23.09.2026

• FDA grants priority review to Insmed's Arikayce sNDA for MAC lung disease (öffnet in neuem Tab)

  Dealroom · 22.09.2026

• Insmed's Brinsupri hits $517M sales; strong pip... (öffnet in neuem Tab)

  Pluang · 22.09.2026

• FDA Accepts Insmed's Filing Seeking Label Expansion for Arikayce (öffnet in neuem Tab)

  Yahoo Finance · 22.09.2026

• Insmed stock price target maintained at $195 by Mizuho on FDA review (öffnet in neuem Tab)

  Investing.com · 22.09.2026

• Insmed: Expensive Stock, But Discount To Recent Highs Makes Bull Case (NASDAQ:INSM) (öffnet in neuem Tab)

  Seeking Alpha · 22.09.2026

• Discipline and Rules-Based Execution in INSM Response (öffnet in neuem Tab)

  Stock Traders Daily · 22.09.2026

• FDA Grants Priority Review To Insmed's SNDA For Arikayce For Treatment Of Mac Lung Disease With PDUFA Target Action Date Set For January 28, 2027 (öffnet in neuem Tab)

  TradingView · 21.09.2026

• Insmed receives FDA Priority Review for MAC lung therapy after stock ends session down 3% (öffnet in neuem Tab)

  Traders Union · 21.09.2026

• Insmed Incorporated (INSM) Stock Report: A Biotech Powerhouse with 66% Potential Upside (öffnet in neuem Tab)

  DirectorsTalk Interviews · 21.09.2026

• Why is Insmed stock climbing today? (öffnet in neuem Tab)

  Investing.com · 21.09.2026

• FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027 (öffnet in neuem Tab)

  Insmed Incorporated Investor Relations · 21.09.2026

• Did FDA Priority Review of ARIKAYCE ENCORE Data Just Shift Insmed's (INSM) Investment Narrative? (öffnet in neuem Tab)

  Yahoo Finance · 21.09.2026

• Insmed Says FDA Grants Priority Review to Arikayce Supplemental Filing for MAC Lung Disease (öffnet in neuem Tab)

  Yahoo Finance · 21.09.2026

• Insmed stock rises on FDA priority review for Arikayce (öffnet in neuem Tab)

  Investing.com · 21.09.2026

• Insmed stock slips after strong earnings surprise and rich valuation debate (öffnet in neuem Tab)

  AD HOC NEWS · 19.09.2026

• 1,350 employees help 50 nonprofits in one day. Insmed volunteers log 15,000 hours. (öffnet in neuem Tab)

  Stock Titan · 16.09.2026

• Insmed Expands Community Impact During Fifth Annual Global Day of Good (öffnet in neuem Tab)

  Yahoo Finance · 16.09.2026

• The Fund Exited Insmed (INSM) After the Investment Thesis Played Out (öffnet in neuem Tab)

  Yahoo Finance · 16.09.2026

• Insmed at Morgan Stanley global healthcare conference: launch momentum builds (öffnet in neuem Tab)

  Investing.com · 14.09.2026

• Insmed (INSM) director sells 25,000 shares in open-market deal (öffnet in neuem Tab)

  Stock Titan · 11.09.2026